Acute CPP Crystal Arthritis in One or Two Joints: When Initial Anti-Inflammatory Treatment Has Not Resolved the Flare

This protocol is for patients with acute calcium pyrophosphate (CPP) crystal arthritis affecting one or two joints, in whom a first-line anti-inflammatory course did not achieve flare resolution within the expected window. It defines what the next step looks like after that failure.

Clinical Scenario

Acute CPP crystal arthritis with one or two joints involved. For this presentation, joint aspiration and intra-articular glucocorticoid injection are part of the recommended approach.

Previous Treatment — Flare Not Resolved

The prior treatment line — which could include NSAIDs, oral colchicine, oral prednisone, or intramuscular triamcinolone — did not achieve resolution of the acute flare within 7–14 days. That unmet goal is the trigger for escalation to this next protocol.

Next-Step Approach (Partial — Full Regimen Behind the Link)

When acute CPP arthritis is refractory to initial agents, the approach involves a targeted interleukin-1 receptor antagonist. The complete regimen — including drug, dosing schedule, and duration — is available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3389/fmed.2024.1327715

For patients with acute CPP arthritis that affects one or two joints, joint aspiration and intraarticular glucocorticoid injection are suggested.

In patients with refractory acute CPP, arthritis may be treated with anakinra.

Anakinra is an IL-1 receptor antagonist (IL-1Ra) that is administered as a daily 100 mg subcutaneous injection.

Typically, a 3-day regimen has been used to treat acute attacks.

View source ↗